Viyash Scientific Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
VIYASH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.9 pts more than Nifty Microcap 250 and 10.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Viyash Scientific Limited reported standalone revenue of ₹13,820.60 million for FY 2025-26, up 5.5% from restated ₹13,103.40 million in the previous year. Standalone profit after tax (PAT) grew 29.7% to ₹758.70 million from restated ₹584.90 million. The company declared an unmodified auditor opinion with an emphasis of matter regarding the Composite Scheme of Amalgamation that became effective on December 16, 2025, merging multiple subsidiaries (Viyash Life Sciences, Symed Labs, and others) into the company. The board approved grant of 1.31 crore stock options under ESOS 2026 and adopted new Articles of Association. No dividend was recommended for FY 2025-26. Prior period figures have been restated to reflect the amalgamation from April 1, 2024.
The 30% PAT growth demonstrates strong operational performance post-amalgamation, though the significant stock option grant may dilute earnings per share. Investors should note the restated financials and exceptional items including ₹442.10 million profit from asset sales and scheme-related costs affecting comparability.